Cancer drug developer Peloton Therapeutics has appointed Mohammad Hirmand to the position of chief medical officer. He will start his new role at the Dallas-based company on May 1. Hirmand most recently served as chief medical officer of San Francisco-based Medivation, which Pfizer (NYSE: [[ticker:PFE]]) acquired last year in a $14 billion deal.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
